🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

20 recruiting trials

for Short Gut Syndrome

Fiber Food Introduction in Pediatric Short Bowel Syndrome NCT05432648NA1 site📍 Philadelphia Children's Hospital of Philadelphia · Tests: Green bean puree Phase IV Study of rhGH Injection in Adult Short Bowel Syndrome NCT07691125Phase 42 sites📍 Xiamen📍 Nanjing Changchun GeneScience Pharmaceutical Co., Ltd. · Tests: rhGH injection Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS NCT07197944Phase 333 sites📍 Chicago📍 St Louis📍 Omaha Zealand Pharma · Tests: Glepaglutide, Placebo Resting Energy Expenditure by Gastrointestinal Functional Status NCT07714499NA1 site📍 Ljubljana Institute of Oncology Ljubljana · Tests: Protocol-Defined Metabolic and Body Composition Assessment SBS DISK- Creation of a Quality of Life Tool for Short Bowel Patients Compared With a Validated Quality of Life Questionnaire (SBS QoL) NCT06771505n/a1 site📍 Pierre-Bénite Hospices Civils de Lyon Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects NCT04775706Phase 215 sites📍 Boston📍 Cleveland📍 Leuven Hanmi Pharmaceutical Company Limited · Tests: HM15912 Active, Placebo Prospective Multisite Study of Quality of Life in Pediatric Intestinal Failure NCT04629014n/a14 sites📍 Birmingham📍 Aurora📍 Hartford Boston Children's Hospital Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a2 sites📍 Sioux Falls📍 Sydney Sanford Health TED_ORG: Study on Short Bowel Syndrome NCT07400783NA1 site📍 Florence Meyer Children's Hospital IRCCS · Tests: Teduglutide (ALX-0600), No Treatment Added Short-Chain Fatty Acids in Lypopolysaccharide-Induced Inflammation and Executive Function NCT07713641NA1 site📍 Leuven Universitaire Ziekenhuizen KU Leuven · Tests: Short-Chain Fatty Acid Colon-Delivery Capsules, Placebo capsules, Lipopolysaccharide (LPS) A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB NCT03530852NA2 sites📍 Los Angeles📍 Boston Boston Children's Hospital · Tests: Relizorb Elemental 028 Extra Case Studies NCT06877923NA1 site📍 Trowbridge Nutricia UK Ltd · Tests: Elemental 028 Extra Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC) NCT06904872Phase 28 sites📍 Aachen📍 Berlin📍 Essen Napo Therapeutics, S.p.A. · Tests: Crofelemer Powder for Oral Solution, Matched Placebo Powder for Oral Solution AGE Accumulation in Patients on Long-term Parenteral Nutrition NCT07392801NA3 sites📍 Bordeaux📍 Paris📍 Pessac University Hospital, Bordeaux · Tests: Non-invasive skin AGE measurements A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome NCT07319832n/a4 sites📍 Guangzhou📍 Shanghai📍 Shanghai Takeda · Tests: No Intervention Irritable Bowel Syndrome and Control Volunteers: Diet Challenge NCT06668922NA1 site📍 Los Angeles University of California, Los Angeles · Tests: Inulin A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF) NCT07742735Phase 394 sites📍 Los Angeles📍 Denver📍 Washington D.C. VectivBio AG · Tests: Apraglutide, Placebo A Clinical Study of FT1 in Patients With Short Bowel Syndrome NCT07704047Phase 21 site📍 Nanjing Chongqing Peg-Bio Biopharm Co., Ltd. · Tests: FT1, Placebo Kodo Millet Porridge and Its Effects on Gut Health and Metabolic Syndrome NCT07703371NA1 site📍 Mysore JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RE… · Tests: Kodo Millet Porridge Beverage A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome NCT05535361NA5 sites📍 Palo Alto📍 San Francisco📍 Washington D.C. Eclipse Regenesis, Inc. · Tests: Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy